These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 29739801

  • 21. Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012-2018).
    Liu Y, Lv X, Xie N, Fang Z, Ren W, Gong Y, Jin Y, Zhang J.
    BMC Cardiovasc Disord; 2020 Apr 25; 20(1):201. PubMed ID: 32334525
    [Abstract] [Full Text] [Related]

  • 22. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM.
    Circ Cardiovasc Qual Outcomes; 2018 May 25; 11(5):e004652. PubMed ID: 29748356
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the impact of the recent controversy over statins in France: the EVANS study.
    Saib A, Sabbah L, Perdrix L, Blanchard D, Danchin N, Puymirat E.
    Arch Cardiovasc Dis; 2013 Oct 25; 106(10):511-6. PubMed ID: 24080324
    [Abstract] [Full Text] [Related]

  • 24. Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry.
    Bradley CK, Wang TY, Li S, Robinson JG, Roger VL, Goldberg AC, Virani SS, Louie MJ, Lee LV, Peterson ED, Navar AM.
    J Am Heart Assoc; 2019 Apr 02; 8(7):e011765. PubMed ID: 30913959
    [Abstract] [Full Text] [Related]

  • 25. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease.
    Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA.
    JAMA Cardiol; 2017 Jan 01; 2(1):47-54. PubMed ID: 27829091
    [Abstract] [Full Text] [Related]

  • 26. Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths.
    Virani SS.
    Tex Heart Inst J; 2013 Jan 01; 40(3):288-9. PubMed ID: 23914021
    [No Abstract] [Full Text] [Related]

  • 27. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA, Möhlenkamp S, Lehmann N, Kälsch H, Dykun I, Pundt N, Moebus S, Jöckel KH, Erbel R, Heinz Nixdorf Recall Study Investigators.
    JACC Cardiovasc Imaging; 2017 Feb 01; 10(2):143-153. PubMed ID: 27665163
    [Abstract] [Full Text] [Related]

  • 28. Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus.
    Giustino G, Colantonio LD, Brown TM, Carson AP, Dai Y, Farkouh ME, Monda KL, Muntner P, Rosenson RS.
    Cardiovasc Drugs Ther; 2018 Oct 01; 32(5):453-461. PubMed ID: 30078077
    [Abstract] [Full Text] [Related]

  • 29. American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
    Qureshi WT, Kaplan RC, Swett K, Burke G, Daviglus M, Jung M, Talavera GA, Chirinos DA, Reina SA, Davis S, Rodriguez CJ.
    J Am Heart Assoc; 2017 May 11; 6(5):. PubMed ID: 28495699
    [Abstract] [Full Text] [Related]

  • 30. Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.
    Reynolds TM, Pottle A, Quoraishi SH.
    Vasc Health Risk Manag; 2021 May 11; 17():227-237. PubMed ID: 34054297
    [Abstract] [Full Text] [Related]

  • 31. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M, Ansell D, Averna M, Fanelli F, Gorcyca K, Iorga ŞR, Maggioni AP, Paizis G, Tomic R, Catapano AL.
    Atherosclerosis; 2018 Apr 11; 271():120-127. PubMed ID: 29499359
    [Abstract] [Full Text] [Related]

  • 32. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž, De Backer G, Fras Z, Kotseva K, Tokgözoglu L, Wood D, De Bacquer D, EUROASPIRE Investigators.
    Atherosclerosis; 2016 Mar 11; 246():243-50. PubMed ID: 26812002
    [Abstract] [Full Text] [Related]

  • 33. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.
    Persell SD, Brown T, Lee JY, Shah S, Henley E, Long T, Luther S, Lloyd-Jones DM, Jean-Jacques M, Kandula NR, Sanchez T, Baker DW.
    Circ Cardiovasc Qual Outcomes; 2015 Nov 11; 8(6):560-6. PubMed ID: 26555123
    [Abstract] [Full Text] [Related]

  • 34. Recommended and observed statin use among US adults with and without cancer.
    Kobo O, Michos ED, Roguin A, Bagur R, Gulati M, Mamas MA.
    Eur J Prev Cardiol; 2024 Aug 09; 31(10):1251-1257. PubMed ID: 38332751
    [Abstract] [Full Text] [Related]

  • 35. Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study.
    Yebyo HG, Zappacosta S, Aschmann HE, Haile SR, Puhan MA.
    BMC Cardiovasc Disord; 2020 Sep 17; 20(1):418. PubMed ID: 32942999
    [Abstract] [Full Text] [Related]

  • 36. Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.
    Waheed S, Pollack S, Roth M, Reichek N, Guerci A, Cao JJ.
    Atherosclerosis; 2016 Dec 17; 255():193-199. PubMed ID: 27693004
    [Abstract] [Full Text] [Related]

  • 37. Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry.
    Lowenstern A, Li S, Navar AM, Virani S, Lee LV, Louie MJ, Peterson ED, Wang TY.
    Am Heart J; 2018 Jun 17; 200():118-124. PubMed ID: 29898839
    [Abstract] [Full Text] [Related]

  • 38. Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population-Based Cohort Study.
    Garcia-Gil M, Comas-Cufí M, Blanch J, Martí R, Ponjoan A, Alves-Cabratosa L, Petersen I, Marrugat J, Elosua R, Grau M, Ramos R.
    Clin Pharmacol Ther; 2018 Oct 17; 104(4):719-732. PubMed ID: 29194590
    [Abstract] [Full Text] [Related]

  • 39. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU, Talluri S, Riaz H, Rahman H, Nasir F, Bin Riaz I, Sattur S, Ahmed H, Kaluski E, Krasuski R.
    Eur J Prev Cardiol; 2018 May 17; 25(8):844-853. PubMed ID: 29569492
    [Abstract] [Full Text] [Related]

  • 40. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.
    Burstein B, Altobelli KK, Williams K, Cannon CP, Pencina MJ, Sniderman AD, Thanassoulis G.
    Circulation; 2017 Nov 07; 136(19):1860-1862. PubMed ID: 29109198
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.